KAZIA THERAPEUTICS LTD (KZIA) Form 424B3 — Aug 31, 2026
Kazia Therapeutics filed a 424B3 prospectus supplement on August 31, 2026 to update its December 23, 2025 prospectus (Form F-1, Registration No. 333-290598), which covers 232,956 American Depositary Shares representing 116,478,000 ordinary shares. The supplement incorporates an August 31, 2026 Form 6-K whose only substantive disclosure is that the company launched a new website, www.kaziatx.com, on August 28, 2026, replacing prior references to www.kaziatherapeutics.com. Kazia's ADSs trade on the Nasdaq Capital Market under the symbol KZIA and last reported a sale price of $13.58 per ADS on August 28, 2026.
Key figures
- Shares Offered
- 232,956 American Depositary Shares (representing 116,478,000 ordinary shares)
- Last Reported Sale Price
- $13.58 per ADS on Nasdaq (August 28, 2026)
- Registration Statement
- Form F-1, Registration No. 333-290598, prospectus dated December 23, 2025
- Implied Ads To Ordinary Share Ratio
- 1:500 (derived from 232,956 ADSs representing 116,478,000 ordinary shares)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.